A relação entre o tratamento e a vacinação da COVID-19 e o agravamento ou incidência de complicações cardiovasculares
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Analisar a relação entre tratamento medicamentoso e vacinas da COVID-19 e o agravamento de complicações cardiovasculares. Métodos: Trata-se de uma revisão integrativa realizada entre agosto e novembro de 2023. As bases de dados utilizadas foram: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), National Library of Medicine and National Institutes of Health (PUBMED) e Biblioteca Virtual em Saúde (BVS). Os descritores foram “Heart Diseases”, “Cardiovascular complications”, “COVID-19”, “Treatment” e “SARS-CoV-2” e os operadores booleanos foram “AND”. Excluíram-se os estudos de revisão e foram incluídos artigos escritos entre 2020 e 2023, escritos em inglês e gratuitos. Resultados: Dos 19 artigos estudados, 7 abordaram tratamento medicamentoso, no qual houve melhora no quadro clínico e tempo de sobrevida. Os 12 artigos restantes relacionados à vacina mostram que o risco de complicações cardiovasculares é raro, com maior frequência em jovens homens. Considerações finais: Não se verificou ocorrências significativas de complicações cardiovasculares em pacientes que foram submetidos ao tratamento medicamento ou à vacina contra a doença, sendo ambas essenciais para o combate da doença.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. CASARIN F, et al. AB1348 PERICARDITIS AFTER COVID-19 VACCINATION: a case series. Scientific Abstracts, 2023; 82: 1905.
3. CORRAO G, et al. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in lombardy, italy. Bmc Infectious Diseases, 2022; 22: 844.
4. DEFTEREOS S, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. Jama Network Open, 2020; 3(6): e2013136.
5. FADAH K, et al. Acute Myopericarditis After First Dose of mRNA-1273 SARS-CoV-2 Vaccine in a Young Adult. Cureus, 2023; 12: e02929.
6. FANG E, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduction And Targeted Therapy, 2023; 7: 94.1.
7. FARAHMAND R, et al. Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects. The American Journal of Cardiology, 2022; 164: 123-130.
8. FOLEGATTI P, et al. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 2022; 40: 5248-5262.
9. HAJJO R, et al. Shedding Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines, 2021; 9: 1186.
10. INJAC R, et al. Global pandemic vaccine development, production and distribution challenges for the world population. International Journal Of Risk & Safety In Medicine, 2022; 33: 235-248.
11. KARLSTAD Ø, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. Jama Cardiology, 2022; 7: 600.
12. KLOK F, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 2020; 191: 145-147.
13. KYAW H, et al. COVID-19 mRNA Vaccine-Associated Myocarditis. Cureus, 2022; 14(1): e21009.
14. LOPES R, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. Jama, 2021; 325: 254.
15. MAARSE B, et al. Effect of hydroxychloroquine on the cardiac ventricular repolarization: a randomized clinical trial. British Journal of Clinical Pharmacology, 2021; 88: 1054-1062.
16. MARSHALL M, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics. 2021; 148(3): e2021052478
17. NÚÑEZ-GIL I, et al. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international hope covid-19 (health outcome predictive evaluation for covid-19) registry. American Heart Journal, 2021; 237: 104-115.
18. OSTROWSKI S, et al. Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. Frontiers In Immunology, 2021; 12.
19. PATONE M, et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation, 2022; 146: 743-754.
20. PRISMA. 2023. Disponível em:
21. SCHATZMAYR H. Novas perspectivas em vacinas virais. História, Ciências, Saúde-Manguinhos, 2003; 10: 655-669.
22. TAVARES C, et al. Alterações da ECA2 e Fatores de Risco para Gravidade da COVID-19 em Pacientes com Idade Avançada. Arquivos Brasileiros de Cardiologia, 2020; 115: 701-707.
23. WANG T, et al. Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. Annals Of Internal Medicine, 2023; 176: 515-523.
24. WITBERG G, et al. Myocarditis after COVID-19 Vaccination in a Large Health Care Organization. New England Journal of Medicine, 2021; 385: 2132-2139
25. YE X, et al. BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS‐CoV‐2 Infection Among Patients With Cardiovascular Disease. Journal of the American Heart Association, 2023; 12.